Clinical Trial Update: Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) [Phase 3]

View source ↗

Summary

A Phase 3 study assessing nemvaleukin alfa in combination with pembrolizumab for platinum-resistant ovarian cancer has been terminated. Results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Peritoneal Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Nemvaleukin alfa (nemvaleukin alfa)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mural Oncology, Inc | Conditions: Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Status: TERMINATED | Results posted: 2025-08-28